|
|
Article: Othera Pharmaceuticals and the National Eye Institute Reach Target Enrollment in Dry AMD Clinical Trial with OT-551 Eye Drops.
- Article from:
- Business Wire
- Article date:
- June 18, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Othera's Lead Compound is Being Tested in 10 Patients with Bilateral (Both Eyes) Geographic Atrophy (GA), a Severe Form of Dry Age-Related Macular Degeneration (AMD). AMD is the Leading Cause of Blindness in America in Persons over Age 55 and the Dry Form Represents Nearly 90% of All AMD Cases
EXTON, Pa. -- Othera Pharmaceuticals, Inc. today announced that an open label clinical study of OT-551 in patients with bilateral Geographic Atrophy (GA) has reached its enrollment target of 10 patients. OT-551 is Othera's lead small molecule topical eye drop currently in development for treating the dry and wet forms of age-related macular degeneration (AMD) and cataracts. ...
Related newspaper, magazine, and journal articles:
|
|
Article: Othera Pharmaceuticals Announces Upcoming ...
Business Wire;
April 19, 2007 ;
700+ words
...Data on OT-551's Inhibition ... Switzerland EXTON, Pa. -- Othera Pharmaceuticals, Inc. today announced ... s lead compound, OT-551, and related ... compounds from the OT-300 Program at the ... these compounds. About Othera Pharmaceuticals Othera Pharmaceuticals ...
|
|